Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

The Harbor Long Term Growers ETF returned 5.97% underperforming the benchmark, the Russell 1000 Growth Index, which returned ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...